Since Brugada syndrome was identified in 1992, its therapeutic management of patients has presented a great challenge for clinicians.1

In this issue of Circulation Arrhythmia and Electrophysiology, Belhassen et al2 suggest both risk stratification of arrhythmia and therapeutic improvements using electrophysiological study (EPS) and quinidine.

Although gradual progress in risk stratification at the population level has been reached through the creation of large databases,3–5 we must admit that >30 years after its first description, arrhythmic risk assessment and, therefore, the best treatment choice in a patient affected by Brugada syndrome still remain a real challenge for clinicians.

There are many factors that come into play in the treatment of Brugada syndrome. First, clinical diagnosis of Brugada syndrome is sometimes difficult and usually overestimated because it is based on the ECG aspect.6 After diagnosis, the main feature is the risk of ventricular fibrillation. However, events can be distant from each other—sometimes >20 years between 2 arrhythmic events.5 Moreover, although a trigger can be found in most arrhythmic diseases, it is rare in Brugada syndrome patients, making the prediction of such an event uncertain.6

In fact, the main challenge in evaluating patients affected with Brugada syndrome is the relatively low incidence of events. For instance, in the FINGER registry, patients who experienced cardiac arrest had a 7.7% event rate per year, patients with syncope had 1.9%, and asymptomatic patients had 0.5%.5 This risk seems to be cumulative over time and reaches a 12% risk at 10 years in asymptomatic patients with a spontaneous aspect of Brugada syndrome.5 This points to a relatively low annual risk, but a relatively high lifetime risk of arrhythmia. A large cohort and long-term follow-up in studies involving asymptomatic patients are therefore needed.

Finally, since description of Brugada syndrome occurred in this era of implantable cardiac defibrillator (ICD), they have been the main therapy in Brugada syndrome patients up to now. Thus, other therapeutic alternatives, such as quinidine, have not been properly evaluated despite some interesting data.3,9

In this issue, Belhassen et al2 reported their experience in the management of patients affected by the Brugada syndrome over a period of >30 years.

The particular interest of this work is that the treatment given to their patients was different from what is usually performed and proposed in different consensus conferences.6 Indeed, the treatment was based on an aggressive electrophysiological study to induce ventricular fibrillation, and if ventricular fibrillation was induced, the patient was then treated with quinidine to obtain a negative EPS.

In case of negative EPS, a quinidine treatment was proposed to the patient without ICD implantation even in the case of cardiac arrest. Using this approach, the authors obtained excellent results because no cardiovascular deaths occurred during the mean follow-up of 113 months.

The study raises 2 interesting questions: (1) What is the value of EPS to determine the arrhythmic risk in a patient with Brugada syndrome? and (2) Is quinidine a safe alternative to ICD to prevent sudden death?

The first question has been debated for years. Up to now, most of the studies on this topic have consisted in performing EPS and implanting an ICD if the EPS was positive. Therefore, all of these studies have a major bias in terms of the way the follow-up was performed depending on the results of the EPS. If the EPS was positive, the patient was implanted with an ICD, and he or she then benefitted from a perfect follow-up with a continuous recording of the ECG. On the contrary, if the EPS was negative, no treatment was proposed, and the patient only had yearly clinical follow-up. It is clear that the chance of detecting an arrhythmic event is not the same in these 2 situations, in particular, owing to self-limited ventricular arrhythmia that can be asymptomatic. This may, at least in part, explain the positive results of EPS in studies that did not include ICD implantation in the evaluation of the value of EPS. This is also probably the reason that the only prospective study to evaluate EPS was negative.4 This study also underlies questions about reproducibility of a positive EPS, with standard protocol, achieved in only one-third of patients.4

The study by the Belhassen group should be of particular interest to resolve this debate. However, the protocol used in the study is extremely aggressive and different from what is usually performed. Therefore, the percentage of inducible patients was extremely high (100% in aborted cardiac arrest patients, 74% in case of syncope, and 61% in asymptomatic patients). In that case, it is difficult to evaluate the value of EPS because the group with a negative EPS was too small (only 20 patients).

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the L’institut du thorax, INSERM U1087, CHU de Nantes, Nantes, France.

Correspondence to Vincent Probst, MD, PhD, L’institut du thorax, INSERM U1087, CHU de Nantes, Service de cardiologie du CHU de Nantes, Bd Monod 44093 Nantes cedex 01, France. E-mail Vincent.probst@chu-nantes.fr

(Circ Arrhythm Electrophysiol. 2015;8:1309-1310. DOI: 10.1161/CIRCEP.115.003576.)

© 2015 American Heart Association, Inc.

Circ Arrhythm Electrophysiol is available at http://circbp.ahajournals.org
DOI: 10.1161/CIRCEP.115.003576
Regarding this study, it could be tempting to consider quinidine as a safe alternative to the implantation of an ICD. Unfortunately, it is probably not so simple!

Indeed, a large proportion of the patients included in the study were asymptomatic without a spontaneous aspect of Brugada syndrome (50 patients). This sort of patient is not usually treated at all because the risk of a cardiac event is low and the guidelines only propose annual follow-up.

For the rest of the population and more specifically the patients who experienced sudden cardiac death, it is difficult to draw a definite conclusion on the possibility of avoiding ICD implantation. The population was relatively small, and more importantly, only 2 patients were treated with a class 1 anti-arrhythmic drug alone at the end of the study with 6 of 10 patients ultimately receiving an ICD.

There are several reasons that so few patients remained on class 1 anti-arrhythmic drug only. First, many patients experienced side effects (38%) that led to the discontinuation of treatment. It is also certain that in this situation of high risk of sudden death, it would be disquieting for the patients to be without the protection of an ICD.

Finally, the question raised by this work is the following: do we really need a medical alternative to ICD implantation? The answer is certainly yes if the treatment is highly efficient and well tolerated. However, regarding the frequent side effects of quinidine, this drug is probably not the perfect candidate. Furthermore, a recent study failed to demonstrate a beneficial effect of quinidine treatment in Brugada syndrome patients.10 However, ICD technology has made significant progress over the last year in terms of battery longevity and inappropriate shocks with a dramatic reduction of their frequency using remote monitoring and good programming of the ICD. It is true that lead failure in this young and active population remains the main challenge. One can expect that the possibility now offered by subcutaneous ICD will solve this problem even if the experience with this type of device is still limited, and the frequency of inappropriate shocks a matter of concern.

In any case, Belhassen et al must be thanked for the originality and the novelty of the work presented in the journal. Quinidine is of great interest in case of an electrical storm and the novelty of the work presented in the journal. Management of Brugada syndrome: thirty-three-year experience using electrophysiologically guided therapy with class 1A antiarrhythmic drugs. Circ Arrhythm Electrophysiol. 2015;8:1393–1402. doi: 10.1161/CIRCEP.115.003109.


Key Words: Editorials ▪ Brugada syndrome ▪ risk assessment ▪ therapeutics ▪ quinidine

Disclosures

Dr Probst is a consultant for Boston Scientific and Medtronic and has received a research grant from Boston scientific and a research grant from Sanofi. Dr Gourraud reports no conflicts.
Quinidine in Brugada Syndrome: Still a Long Way to Go…
Vincent Probst and Jean-Baptiste Gourraud

Circ Arrhythm Electrophysiol. 2015;8:1309-1310
doi: 10.1161/CIRCEP.115.003576
Circulation: Arrhythmia and Electrophysiology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3149. Online ISSN: 1941-3084

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circep.ahajournals.org/content/8/6/1309

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Arrhythmia and Electrophysiology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Arrhythmia and Electrophysiology is online at:
http://circep.ahajournals.org//subscriptions/